5 pending office actions
| App # | Title | Examiner | Art Unit | Status | Filed |
|---|---|---|---|---|---|
| 18543912 | PSGL-1 Antagonists and Uses Thereof | LANDSMAN, ROBERT S | 1647 | Non-Final OA | Dec 18, 2023 |
| 18248979 | ANTI-C-C CHEMOKINE RECEPTOR 8 (CCR8) ANTIBODIES AND METHODS OF USE THEREOF | FAUST, AMBER KATHLEEN | 1643 | Non-Final OA | Apr 13, 2023 |
| 17818256 | FGFR2 INHIBITORS ALONE OR IN COMBINATION WITH IMMUNE STIMULATING AGENTS IN CANCER TREATMENT | DUFFY, BRADLEY | 1643 | Final Rejection | Aug 08, 2022 |
| 17773800 | CD80 EXTRACELLULAR DOMAIN FC FUSION PROTEIN REGIMENS | DENT, ALANA HARRIS | 1643 | Non-Final OA | May 02, 2022 |
| 17282589 | Anti-FGFR2 Antibody Formulations | SKOKO III, JOHN JOSEPH | 1643 | Non-Final OA | Apr 02, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial